# A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL)

> **NCT00596258** · PHASE2 · COMPLETED · sponsor: **Tigris Pharmaceuticals** · enrollment: 11 (actual)

## Conditions studied

- Cervical Intraepithelial Neoplasia
- Uterine Cervical Dysplasia

## Interventions

- **DRUG:** A-007

## Key facts

- **NCT ID:** NCT00596258
- **Lead sponsor:** Tigris Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2008-07
- **Final completion:** 2008-08
- **Target enrollment:** 11 (ACTUAL)
- **Last updated:** 2009-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00596258

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00596258, "A Two-Stage Phase 2 Study Of A-007 Topical Gel in High-Grade Squamous Intraepithelial Lesions (HSIL)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00596258. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*